Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 3/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28454727 | 0.88 | PDPK1 (0.44) | CTSDBACE1PDPK1PRMT5 | |
| SCHEMBL8277766 | 0.86 | BACE1 (0.46) | CTSDBACE1ACHEKCNA5OPRK1 | |
| SCHEMBL11924853 | 0.79 | CTSD (0.51) | CTSDBACE1KCNA5OPRK1 | |
| SCHEMBL5713886 | 0.79 | DRD2 (0.41) | CTSDBACE1KCNA5DRD2DRD1 | |
| SCHEMBL14614701 | 0.78 | MAOA (0.52) | PDPK1ACHE | |
| SCHEMBL19521127 | 0.78 | PDPK1 (0.46) | PDPK1ACHE | |
| SCHEMBL3985112 | 0.78 | PDPK1 (0.46) | PDPK1ACHE | |
| SCHEMBL6330755 | 0.78 | ACHE (0.50) | CTSDBACE1ACHEDRD2DRD1 | |
| SCHEMBL3170918 | 0.78 | DRD2 (0.43) | CTSDBACE1ACHEKCNA5DRD2 | |
| SCHEMBL6325800 | 0.78 | DRD2 (0.43) | CTSDBACE1ACHEKCNA5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004094384-A2 | (HETERO) ARYLAMIDE 2-HYDROXY-3-DIAMINOALKANES FOR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |